AIM
AIM ImmunoTech Inc.
About: AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Employees: 23
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
68% less funds holding
Funds holding: 34 [Q1] → 11 (-23) [Q2]
82% less capital invested
Capital invested by funds: $590K [Q1] → $105K (-$485K) [Q2]
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 24
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for AIM.
Financial journalist opinion
Based on 6 articles about AIM published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025.
Neutral
GlobeNewsWire
2 weeks ago
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
There will be presentations on the latest positive progress from AIM's clinical program in pancreatic cancer, the positive therapeutic effects of AIM's drug Ampligen on multiple cancer types, and Ampligen's mechanism of action in oncology
Neutral
GlobeNewsWire
3 weeks ago
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval.
Positive
Benzinga
4 weeks ago
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM's drug Ampligen at the recent U.S.-Poland Science and Technology Symposium 2025 , held June 17–20, 2025, across Silicon Valley, San Francisco and Stanford University. Pawel Kalinski, MD, PhD, a world-renowned research oncologist, presented on the drug and participated in a discussion session titled Revolution in Healthcare.
Neutral
GlobeNewsWire
2 months ago
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025
Neutral
GlobeNewsWire
2 months ago
AIM ImmunoTech Resumes Trading on NYSE American
Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th
Neutral
GlobeNewsWire
2 months ago
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No.
Charts implemented using Lightweight Charts™